GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Selling, General, & Admin. Expense

Biotechnology Assets (XMAD:BST) Selling, General, & Admin. Expense : €0.50 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Biotechnology Assets's selling, general, & admin. expense for the six months ended in Dec. 2023 was €0.18 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.50 Mil.


Biotechnology Assets Selling, General, & Admin. Expense Historical Data

The historical data trend for Biotechnology Assets's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets Selling, General, & Admin. Expense Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.39 0.95 0.62 0.50

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.33 0.29 0.32 0.18

Competitive Comparison of Biotechnology Assets's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Biotechnology Assets's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotechnology Assets's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's Selling, General, & Admin. Expense falls into.



Biotechnology Assets Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotechnology Assets  (XMAD:BST) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Biotechnology Assets Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotechnology Assets (XMAD:BST) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.